Introduction
Artificial intelligence (AI) is increasingly discussed as a potential component of future mental health care systems. Although rule‑based clinical decision support tools—such as decision or classification trees and early “expert systems”—have existed in psychiatry for decades, recent attention has focused primarily on generative AI, particularly large language models (LLMs) such as GPT‑type systems. These models are frequently deployed through conversational interfaces (e.g., chatbots) and are being explored for applications including clinical documentation support, patient triage, psychoeducation, and clinician decision assistance. Across Europe, however, the use, governance, readiness, and acceptability of these newer forms of AI in clinical psychiatry vary substantially, reflecting differences in health system organisation, legal and regulatory frameworks, digital infrastructure, workforce capacity, and cultural context. The purpose of this survey is not to compare or rank countries, nor to evaluate specific technologies or commercial vendors. Rather, it seeks to capture system‑level perspectives on current experiences, perceived challenges, and strategic priorities related specifically to the introduction of generative AI and LLM‑based tools in clinical psychiatry across Europe. The findings will inform an EPA Guidance document intended to support responsible, equitable, and context‑sensitive implementation, rather than to establish prescriptive standards. Responses should reflect the situation in your country or region from the perspective of a national psychiatric association representative or delegated expert. Where information is unavailable or not applicable, please indicate this accordingly.
Estimated completion time: 15–20 minutes.
